Authors

Amit Patel, BSc, MBBS, PhD, The Christie NHS Foundation Trust

Latest:

Research on CAR T Therapy in Earlier Lines of Treatment

Amit Patel, BSc, MBBS, PhD, discusses currently ongoing clinical trials of CAR T-cell therapy in first- and second-line treatment settings and comments on potential developments on the horizon.

Evandro D. Bezerra, MD

Latest:

Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

The key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.

Laith Abushahin, MD

Latest:

Dr Abushahin on Biomarker Testing in mCRC

Laith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.

James A. DeCaprio, MD

Latest:

Extending the Frontiers of Checkpoint Inhibition in Merkel Cell Carcinoma

In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.

Inhye Ahn, MD

Latest:

Dr. Ahn on Choosing Between Treatment Options in CLL

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Uwe Platzbecker, MD

Latest:

Dr Platzbecker on First-Line ATRA/ATO in High-Risk Acute Promyelocytic Leukemia

Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.

Aurélien Marabelle, MD, PhD

Latest:

Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.

Karim Chamie, MD

Latest:

Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBC

Karim Chamie, MD, discusses the FDA approval of nogapendekin alfa plus BCG for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Ulka N. Vaishampayan, MBBS, FAB

Latest:

Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.

Wen Wee Ma, MBBS

Latest:

Dr. Ma on First-Line Treatment Considerations in Metastatic Pancreatic Cancer

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

Deric L. Wheeler, PhD

Latest:

Window of Opportunity Trials Are Needed for Novel Tissue Biomarker Analysis in Head and Neck Cancers

Drug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.

Hannah Choe, MD

Latest:

Clinical Scenario and Perspectives on the Evolving Treatment Landscape in GVHD

Dr. Hannah Choe discusses a clinical scenario of a patient with GVHD who has progressed after multiple lines of treatment. She explores how the availability of CSF-1R inhibitors could fit into the evolving treatment landscape for managing this difficult-to-treat patient population. Dr. Choe provides her perspectives on the potential role and clinical implications of targeting this pathway as an emerging therapeutic approach for GVHD.

Jaime R. Merchán, MD

Latest:

Dr Merchán on the Future Treatment of Advanced RCC

Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.

Alexander E. Perl, MD, University of Pennsylvania

Latest:

Future Treatment Landscape of AML

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

James Knight, MD

Latest:

Dr Knight on Diagnosing and Managing Brain-Metastatic Prostate Adenocarcinoma

James Knight, MD, discusses a case study of a patient with brain-metastatic prostate adenocarcinoma.

Cesar Gentille Sanchez, MD

Latest:

Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia

The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.

Caroline Kuhlman, NP

Latest:

FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

George Yaghmour, MD

Latest:

Blinatumomab Plus Chemo in Newly Diagnosed, Standard-Risk Pediatric B-ALL

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.

David Planchard, MD, PhD, Gustave Roussy Institute of Oncology

Latest:

Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Michelle Melisko, MD

Latest:

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.